To explore the clinical value of 18F-CYP2108 in PET quantitative imaging of brain cholesterol 24 hydroxylase (CYP46A1) and imaging localization of epileptic focus caused by drug resistant epilepsy.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064661

Enrollment

Unknown

Registered

2022-10-13

Start date

2022-10-10

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Experimental group:Standard surgical treatment and PET/CT brain imaging

Control group:PET/CT brain imaging

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for healthy volunteers: regardless of gender, between 20 and 40 years old, without basic diseases or mental diseases. 2. Inclusion criteria for patients with epilepsy: the age is between 18 and 65 years old, regardless of gender; Patients with drug-refractory epilepsy who need surgery; EEG is positive; The epileptic focus caused by brain magnetic resonance (MRI) was positive or negative; EEG and MRI showed that unilateral epileptogenic focus was the best.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria for healthy volunteers: there are basic diseases and mental diseases, and MRI examination shows abnormal brain function and structure. 2. Exclusion criteria for epilepsy patients: epilepsy patients with neurodegenerative diseases, brain tumors, and other diseases were excluded.

Design outcomes

Primary

Measure	Time frame
PET/CT normalized uptake value;Electroencephalogram (EEG);Brain MRI;	—

Countries

China

Contacts

Public ContactLu Wang

The First Affiliated Hospital of Jinan University

l_wang1009@jnu.edu.cn+86 13326498671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026